Assistant Professor at Mayo Clinic | Cancer Immunology
Joined April 2016
- Tweets 156
- Following 337
- Followers 322
- Likes 588
41 Photos and videos
Pinned Tweet
1 Feb 2023
Today the Ager Lab at @MayoClinic officially opened its doors! So thrilled to start this adventure, and thankful to friends and mentors that helped me get here.
I’m recruiting at all levels, so please RT to spread the word! More info at our website:
AgerLab.com
16
38
242
41,367
Casey Ager retweeted
Congratulations to Dr. Casey Ager and his lab for their first R01 from the NCI! The 5-year grant is to study the role of TRPS1 in antitumor activity. This will hopefully lead to the discovery of a new therapeutic target for GU cancers and potentially other cancer types.
2
3
12
1,288
Casey Ager retweeted
Online now: Neoadjuvant Fc-enhanced anti-CTLA-4 targets Tregs to augment androgen deprivation in high-risk prostate cancer: A randomized phase I trial dlvr.it/TRDh59
3
7
517
Feb 28
Great work @ZakhariaYousef!
Feb 27
Cancers of the reproductive and urinary organs, known as genitourinary cancers, affect millions of people worldwide each year. At Mayo Clinic, Yousef Zakharia, M.D., a medical oncologist and chair of the Genitourinary Disease Group at the Mayo Clinic Comprehensive Cancer Center, leads clinical research aimed at improving outcomes for patients with kidney, bladder and prostate cancers.
Learn more: mayocl.in/4r18kz4
1
200
Feb 27
Thanks @MayoClinic for the highlight. We’re thrilled to see this out!
For any interested in reading deeper, the study in full can be accessed here: cell.com/cell-reports-medici…
#ASCOGU2026
Feb 26
A Mayo Clinic-led study in Cell Reports Medicine shows a new immunotherapy hormone therapy combo could overcome a major barrier in early-stage prostate cancer treatment, offering hope for patients at high risk.
Learn more about this groundbreaking study and its potential impact: mayocl.in/4kXwysE | @caseyager
4
175
Feb 26
🚨Excited to share our latest study on immunotherapy for prostate cancer, out today at @CellRepMed!
We hope this paves the way for further translation of Fc-enhanced CTLA-4 antibodies by showing evidence of tumor Treg depletion in patients.
cell.com/cell-reports-medici…
1
3
12
327
Feb 26
And here’s the link to our prior tweetorial on the pre-print for more detail, with proper shoutouts to our amazing collaborative team:
12 Sep 2024
New pre-print out! 🚨
Targeted Treg depletion has been a long sought-after goal in cancer, with few if any clinical successes to date. Next-gen CTLA-4 drugs have been engineered for this purpose, but do they work? Read on to find out:
🧵 (1/17)
medrxiv.org/content/10.1101/…
1
96
6 Oct 2025
Fitting day to have our first Treg-focused paper from the lab published! Congrats to superstar postdoc Nilika Bhattacharya for her hard work perfecting this 38-marker spectral flow panel to dissect human Treg heterogeneity
onlinelibrary.wiley.com/doi/…
#NobelPrize #Tregs @MayoClinic
4
12
374
Casey Ager retweeted
30 Jul 2025
Delaying the use of ADT in oligorecurrent prostate cancer treated with SBRT but for who? Integration of imaging- and blood-based tumor burden estimation to select the right patients.
@MayoUrology @MayoRadOnc @MayoCancerCare
pubmed.ncbi.nlm.nih.gov/4068…
1
2
10
690
2 Jun 2025
Landmark day in the lab as flow guru and awesome postdoc @CollinJugler runs the first 51-color flow cytometry experiment in lab history! Breaking the 50-marker mark in style with help from our friends at @CytekBio @BDBiosciences #CYTO2025
2
2
28
1,036
Casey Ager retweeted
16 Jan 2025
Excited to share our recent multi-center study showing PSMA EVs are prognostic and predictive in oligometastatic prostate cancer treated with SBRT. Validation studies are ongoing. A future for EV-guided therapy! @MayoUrology @MayoRadOnc
aacrjournals.org/clincancerr…
4
13
47
6,871
1 Oct 2024
Thankful and proud of my awesome team who worked together tirelessly over the last week getting the Ager Lab up and running in our shiny new lab space at @MayoClinic’s new Integrated Education and Research Building (IERB) on Mayo’s Phoenix campus!
3
19
823
12 Sep 2024
Prostate tumors are notoriously poorly immune infiltrated, so access to surgical tissue afforded the rare opportunity for orthogonal immune profiling by CyTOF, scRNAseq and spatial. As in our past work, @califano_lab’s PISCES pipeline brought the scRNAseq data to life.
(6/17)
1
1
261
12 Sep 2024
Another huge thank you to the many additional contributors not called out here that put so much effort into this study. It was as a huge team effort. And of course, thank you most of all to patients and their families for participating in this study! (16/17)
1
1
189
12 Sep 2024
We’d love to hear your feedback! For those interested, my lab at Mayo AZ (@MayoClinic @MayoCancerCare @MayoUrology) is eagerly digging into these mechanisms to develop new and better immunotherapy approaches for prostate cancer. Please join us…. or fund us!! (17/17)
1
166